 |
Biosketch
CURRICULUM VITAE
NINA SINGH, M.D.
BIOGRAPHICAL
Name: Nina Singh, M.D.
Business Address: VA Pittsburgh Healthcare System
Infectious Disease Section
University Dr. C
Pittsburgh, PA 15240
Business Telephone: 412-688-6179
E-mail: nis5@pitt.edu
EDUCATION AND TRAINING
GRADUATE:
1975 1980 Government Medical College M.D.
Amritsar, India
POST GRADUATE:
1981 - 1982 Montefiore University Hospital PGY I Medicine
Pittsburgh, PA
1982 - 1984 St. Francis Medical Center PGY II and III Medicine
Pittsburgh, PA
1985 - 1987 University of Pittsburgh Fellowship Infectious Diseases Medical Center
Pittsburgh, PA
APPOINTMENTS AND POSITIONS
1987 - 1990 St. Francis Medical Center Associate Staff
Pittsburgh, PA Department of Medicine
1987 - 1990 St. Margaret Memorial Hospital Associate Staff
Pittsburgh, PA Department of Medicine
1990 - present VA Healthcare System Chief, Transplant Infectious Diseases
Pittsburgh, PA
2004 - present University of Pittsburgh Associate Professor of Medicine
Pittsburgh, PA (with tenure)
CERTIFICATION and LICENSURE
SPECIALTY CERTIFICATION:
Certifying Board: American Board of Internal Medicine 1984
Subspecialty of Infectious Disease,
American Board of Internal Medicine 1988
MEDICAL or OTHER PROFESSIONAL LICENSURE:
Licensing Board Pennsylvania MD - 029552E 1983
MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES
Infectious Diseases Society of America 1995 –
American Society of Transplantation 2002 –
HONORS
Young Investigator Award for CHEST 1997
(American College of Chest Physicians)
Pfizer Visiting Professor Award 1999, 2003
41st ICAAC Program Committee Award 2001
Senior author of most cited paper in immunology 2003
Institute of Scientific Information (ISI)
Essential Science Indicators (ESI)
First author of paper cited amongst top 1% 2005
in its field (ISI and ESI)
Best Doctors in America 2003-04, 2005-06
Research Honors, VA Research 2004
& Development
100 most accomplished Indian-Americans, 2005
Roshni International
Who’s Who in Medical Science Education 2005
Commendation Award, VA Central Office, 2006
Transplant Program
REFEREED ARTICLES
1. Singh N, Dummer JS, Kusne S, Makowka L, Starzl TE, Ho M. Infections with cytomegalovirus and herpes simplex virus in 121 liver transplant recipients: role of donated organ and impact of OKT3 antibodies. J Infect Dis 1988; 158:124 131.
2. Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Starzl TE, Ho M. Infections in 101 adult liver transplant recipients. Medicine 1988; 67:132 143.
3. Singh N, Dummer JS, Kusne S, Starzl TE, Ho M. Impact of OKT3 on cytomegalovirus and herpes simplex virus in adult liver transplant recipients. Transplant Proc 1988; 20:661 662.
4. Kusne S, Dummer JS, Singh N, Makowka L, Starzl TE, Ho M. Fungal infections in adult liver transplant recipients. Transplant Proc 1988; 20:650 651.
5. Singh N, Yu VL, Rihs JD. Invasive aspergillosis in AIDS. South Med J 1991; 84:
822 827.
6. Singh N, Yu VL. Successful treatment of pulmonary infection due to Mycobacterium chelonae: case report and review. Clin Infect Dis 1992;14:156 161.
7. Singh N, Yu VL. Osteomyelitis due to Veillonella parvula: case report and review. Clin Infect Dis 1992;14:361 363.
8. Mieles LA, Fung JJ, Yokoyama I, McCauley J, Singh N, Todo S, Gordon RD, Starzl TE. Liver transplantation of American veterans under FK506 immunosuppression: A preliminary report. Transplant Proc 1991; 23: 3016 3018.
9. Singh N, Yu VL, Mieles L, Wagener MM. Beta lactam induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease. Am J Med 1993; 94:251 256.
This paper was selected for publication in the Year Book
of Infectious Diseases, 1995.
10. Singh N, Yu VL. Abdominal pain and cholestatic hepatitis in an AIDS patient. Hosp Practice 1993; 28:104 108.
11. Singh N, Anderegg KA, Yu VL. Significance of hypoglycorrhachia in patients with AIDS and cytomegalovirus meningoencephalitis. Clin Infect Dis 1993; 17:283 284.
12. Singh N, Mieles L, Yu VL, Gayowski T. Invasive aspergillosis in liver transplant recipients: Association with candidemia and consumption coagulopathy and failure of prophylaxis with low dose amphotericin B. Clin Infect Dis 1993; 17:906 908.
13. Singh N, Mieles L, Yu VL, Starzl TE. Decreased incidence of viral infections in liver transplant recipients: possible effects of FK 506. Dig Dis Sci 1994; 39:15 18.
14. Singh N, Muder RR, Yu VL, Gayowski T. Legionella infection in liver transplant recipients: implications for management. Transplantation 1993; 56:1549 1551.
15. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. Failure of high dose acyclovir and success of short course preemptive ganciclovir therapy in preventing cytomegalovirus disease in liver transplant recipients: a prospective randomized trial. Ann Intern Med 1994; 120:375 381.
This article was selected for publication in 1995 Year Book of
Medicine and 1996 Year Book of Infectious Diseases.
16. Singh N, Stempel K. Brain herniation in central nervous system toxoplasmosis. (Images in Clinical Medicine) N Engl J Med 1994;331:711.
17. Singh N, Yu VL, Gayowski T. Central nervous system lesions in adult liver transplant recipients: clinical review with implications for management. Medicine 1994; 73:110 118.
18. Singh N, Rihs JD, Gayowski T, Yu VL. Cutaneous cryptococcosis mimicking bacterial cellulitis in a liver transplant recipient: case report and review in solid organ transplant recipients. Clin Transplant 1994;8:365 368.
19. Singh N, Rihs JD, Gayowski T, Mieles L, Yu VL. Superiority of Bactec as compared to conventional cultures for the detection of spontaneous bacterial peritonitis: prospective study comparing two culture methods. Hepatology 1993;18:293A.
20. Singh N, Rihs JD, Gayowski T, Mieles L, Yu VL. Improved detection of spontaneous bacterial peritonitis with Bactec as compared to conventional culture methods: a prospective study. Diagn Microbiol Infect Dis 1994;19:1 4.
21. Singh N, Gayowski T, Wagener M, Yu VL. Infectious complications in liver transplant recipients on tacrolimus: prospective analysis of 88 consecutive liver transplants. Transplantation 1994; 54:774 778.
22. Singh N, Gayowski T, Wagener MM, Ndimbie OK, Nedjar S, Yu VL. Recurrent hepatitis C virus hepatitis in liver transplant recipients: association with increased immunosuppression post transplantation. Surgery 1996; 119:452-456.
23. Singh N, Gayowski T, Yu VL. Herpes zoster virus associated idiopathic thrombocytopenic purpura in a liver transplant recipient: a case report and overview. Transplant International 1995; 8:58 60.
24. Singh N, Squier C, Sivek C, Hayes P, Wagener MM, Goetz A, Nguyen MH, Yu VL. Determinants of compliance in patients with human immunodeficiency syndrome: prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261-269.
25. Singh N, Gayowski T, Singh J, Yu VL. Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report and review in solid organ transplant recipients. Clin Infect Dis 1995; 20:617 620.
26. Singh N, Stempel K. Pneumobilia due to cholecystoduodenal fistula. N Engl J Med 1997; 336:266.
27. Singh N, Yu VL. Potable water and Mycobacterium avium complex in HIV patients: is prevention possible? Lancet 1994;343:1110 1111.
28. Singh N, Gayowski T, Carrigan DR, Singh J. Variant B human herpes virus 6 associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient. Transplantation 1995;60:1355-1357.
29. Singh N, Gayowski T, Wagener M, Yu VL. Trimethoprim sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a prospective randomized trial. Ann Intern Med 1995;122:595-598.
This article was selected for publication in the 1995 Mosby
Yearbook of Medicine, American College of Physicians Journal Club, 1995, and in Infectious Disease Alert, 1995.
30. Singh N, Gayowski T, Schlictig R. Acute adrenal insufficiency in critically ill liver transplant recipients: implications for diagnosis. Transplantation 1995;59:1744-1745.
31. Singh N, Gayowski T. Lack of sustained efficacy of ganciclovir plus foscarnet for hepatitis B virus recurrence after liver transplantation. Transplantation 1995;59:1629-1630.
32. Singh N, Yu VL. Infections in organ transplant recipients. Curr Opinion Infect Dis 1995;8:247-253.
33. Singh N, Squier CS, Sivek C, Wagener MM, Yu VL. Determinants of nontraditional
therapy use in patients with HIV: a prospective study. Arch Intern Med 1996;156:
197-201.
Paper cited in U.S. Medicine, 1996;32 (17):22, and in Federal
Practitioner 1996; October: 71.
34. Singh N, Gayowski T, Marino IR. Hemolytic uremic syndrome in liver transplant recipients receiving tacrolimus: case report and review in solid organ transplant recipients Transplant International 1996;9:68-75.
35. Singh N, Marino IR, Gayowski T. Toxoplasma gondii pneumonia in liver transplant recipient: Implications for diagnosis. Liver Transplantation Surgery 1996;2:299-300.
36. Goetz A, Muder RR, Rihs JD, Chow JW, Singh N. An outbreak of infusion related Klebsiella pneumoniae bacteremia on a liver transplantation service. Clin Infect Dis 1995;21:1501-1503.
37. Chang FY, Singh N, Gayowski T, Marino IR. Parvovirus B19 infection in a liver transplant recipient: case report and review in organ transplant recipients. Clin Transplantation 1996;10:243-247.
38. Singh N, Gayowski T, Wannstedt CF, Marino IR, Wagener MM. Interferon-alpha therapy for hepatitis C virus recurrence after liver transplantation: long-term response with maintenance therapy. Clin Transplantation 1996;10:348-351.
Paper reviewed in J. Surgical Infections: index and
reviews 1996; 5:18.
39. Singh N, Gayowski T, Wagener MM, Marino IR. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 1996;61:402-406.
40. Singh N, Gayowski T, Wagener MM, Marino IR. Pulmonary infections in liver transplant recipients receiving tacrolimus (FK506) a primary immunosuppressive: prospective assessment in 101 consecutive patients. Transplantation 1996;61:396-401.
41. Singh N, Squier C, Sivek C, Wagener MM, Yu VL. Psychosocial stress and depression in older patients with human immunodeficiency virus infection and intravenous drug use. International Journal STD and AIDS, 1997;8:251-255.
42. Gayowski T, Marino IR, Doyle HR, Echeverri L, Mieles L, Todo S, Wagener MM, Singh N, Yu VL, Fung JJ, Starzl TE. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res 1996;60:333-338.
43. Singh N, Carrigan DR. Human herpes virus-6 in transplantation: an emerging pathogen. Ann Intern Med 1996;124:1065-1071.
Paper cited: Literature scan transplantation. 1996;12(3) and
Federal Practitioner 1996;13:66.
This article was selected for publication in 1998 Mosby Year Book
of Infectious Diseases.
44. Singh N, Gayowski T, Wagener MM. Intensive unit care management in liver transplant recipients: beneficial effects on survival and preservation of quality of life. Clin Transplantation 1997;11:113-117.
45. Singh N, Yu VL. Occult Cytomegalovirus laryngitis in organ transplant recipients (editorial). Head Neck Surg 1996;18:457.
46. Singh N, Yu VL. AIDS sclerosing cholangitis. Clin Infect Dis 1996;23:623.
47. Singh N, Yu VL, Wagener MM, Gayowski T. Fever in cirrhosis in 1990's: Prospective assessment with clinical implications. Clinical Infectious Dis 1997; 24:1135-1138.
48. Singh N, Gayowski T, Wagener MM, Marino IR. Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus immunosuppression: prospective study with ecologic and pathogenic implications. Clin Transplantation, 1997;11:66-70.
49. Singh N, Barnish M, Bender BS, Berman S, Wagener MM, Rinaldi M, Yu VL. Low dose fluconazole for primary prophylaxis of cryptococcosis confined to AIDS patients with CD4 < 100/mm3: demonstration of efficacy in a prospective multicenter trial. Clin Infect Dis 1996; 23:1282-1286.
50. Singh N, Gayowski T, Wagener MM, Doyle H, Marino IR. Invasive fungal infections in liver transplant recipients receiving tacrolimus as primary immunosuppression and review of the literature. Clin Infect Dis 1997;24:179-184.
51. Singh N, Yu VL. Infections in organ transplant recipients. Current Opinion Infect Diseases 1996;9:227-229.
52. Singh N, Gayowski T, Wagener MM, Marino IR. Vulnerability to psychologic stress and depression in patients with endstage liver disease due to hepatitis C virus. Clinical Transplantation 1997;11:406-411.
53. Singh N, Gayowski T, Wagener MM, Marino IR. Depression in patients with endstage liver disease: impact on morbidity and outcome. Dig Dis Sci 1997; 42:1421-1427.
54. Gayowski T, Marino IR, Singh N, Doyle HR, Wagener MM, Todo S, Fung JJ, Starzl TE. Orthotopic liver transplantation in U.S. veterans under primary tacrolimus (PrografTM) immnosuppression. Surgical Technology International 1997; 5:223-232.
55. Dominguez EA, Singh N. Late infectious complications of liver transplantation. Infectious Disease Practice for the Clinician 1996; July:49-53.
56. Singh N. Gayowski T, Wagener MM, Marino IR. Bloodstream infections in liver transplant recipients: changing pattern of microbial origin. Clin Transplantation, 1997; 11:275-281.
57. Singh N, Chang FY, Gayowski T, Marino IR. Infections due to dematiaceous fungi
In organ transplant recipients: case report and review. Clin Infect Dis 1997;24:
369-374.
58. Singh N. State of the Science article: Infections in solid-organ transplant recipients. Am J Infect Control 1997;25:409-417.
59. Vargas H, Wang L, Laskus T, Poutous A, Lee R, Demetris A, Dodson F, Casavilla A, Fung J, Gayowski T, Singh N, Marino I, Rakela J. Distribution of infecting HCV genotypes in American end-stage liver disease patients. J Infect Dis 1997; 175:448-450.
60. Gayowski T, Singh N, Marino R, Vargas H, Wagener MM, Morelli F, Wannstedt C, Fung JJ, Rakela J, Starzl TE. Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon alpha therapy and outcome. Transplantation 1997;64:422-426.
61. Singh N, Gayowski T, Wannstedt CF, Wagener MM, Marino IR. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997; 63:1415-1419.
This article was cited in the J Surg Infections index and reviews,
December, 1997
62. Singh N, Gayowski T, Wagener M, Marino R. Outcome of patients with endstage liver disease requiring intensive care unit support; prospective assessment of predictors of mortality. J Gastroenterology 1998; 33:73-79.
63. Singh N, Chang FY, Gayowski T, Wagener MM, Marino IR. Staphylococcus aureus nasal colonization in patients with cirrhosis: prospective assessment of association with infection. Infection Cont Hosp Epidemiol 1998; 19:328-332.
64. Singh N, Arnow PM, Bonham A, Dominguez E, Paterson DL, Pankey G, Wagener MM, Yu VL. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997;64:716-720.
65. Singh N, Gayowski T, Marino IR. Successful treatment of disseminated Cryptococcosis in a liver transplant recipient with fluconazole and 5 flucytosine, an all oral regimen. Transplantation International 1998;11:63-65.
66. Singh N, Chang FY, Gayowski T, Wagener MM, Marino IR. Fever in liver transplant recipients in the 1990's; changing spectrum of clinical etiologies. Clinical Infectious Diseases 1998; 26:59-65.
67. Singh N, Zeevi A, Gayowski T, Marino IR. Late onset cytomegalovirus disease in liver transplant recipients: de novo reativation in recurrent hepatitis C virus hepatitis Transplantation International 1998;11:308-311.
An abbreviated version of the paper was selected for publication in
Hepatitis Review Journal.
68. Singh N, Gayowski T, Wagener MM, Marino IR. Major bacterial infections in liver transplant recipients receiving tacrolimus as primary immunosuppression: predictors of early versus late onset disease. Eur J Clin Micro Infect Dis 1997; 16:821-826.
69. Singh N. Infections in solid organ transplant recipients. Current Opinion Infect Dis 1997; 10:262-267.
70. Paterson DL, Singh N. Interactions of tacrolimus with antimicrobial agents. Clin Infectious Diseases1997; 25:1430-1440.
71. Paterson DL, Singh N, Gayowski T, Marino IR. Pulmonary nodules in liver transplant recipients. Medicine1998; 77:50-58.
This article was cited in A Current Literature 1998: antibacterial research.
72. Singh N, Carrigan DR, Gayowski T, Marino IR. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity. Transplantation 1997;64:674-678.
Paper selected for publication as rapid communication.
73. Paterson DL, Singh N, Gayowski T, Marino IR. Rapidly fatal bacteremia due to Staphylococcus aureus producing both enterotoxins A and B in a liver transplant recipient Clin Infect Dis1997; 25:1481-1482.
74. Singh N, Falestiny M, Rogers P, Reed MJ, Pulaski J, Norris R, Wagener MM, Yu VL. Pulmonary infiltrates in the intensive care unit: predictors and outcome. Chest 1998;114:1129-1136.
Paper selected for publication in European Radiology 1999 (Journal of the European Congress of Radiology).
Also selected for publication in 1999 Mosby Year Book of Critical Care.
75. Singh N, Gayowski T, Wannstedt C, Wagener MM, Marino IR. Interferon-alpha as
prophylaxis for recurrent hepatitis C virus hepatitis after liver transplantation. Transplantation 1998; 75:82-85.
76. Singh N, Yu VL. Oral ganciclovir usage for cytomegalovirus prophylaxis in organ transplant recipients: is emergence of resistance imminent? Dig Dis Sci1998; 43:1190-1192.
77. Paterson D, Dominguez E, Chang FY, Snydman DR, Singh N. Infective endocarditis in solid organ transplant recipients. Clin Infect Dis 1998; 26:689-694.
78. Gayowski T, Singh N, Marino IR, Doyle HR, Wagener MM, Fung JJ, Starzl TE. High risk liver transplantation; predictors of mortality and infectious morbidity. Transplantation 1998; 65:499-504.
79. Singh N, Deng JS. Varicella zoster virus associated leukocytoclastic vasculitis in a liver transplant recipient. Clin Infect Dis 1998;26:839.
Illustrations published in Pathology of Human Viral Disease.
Craighead JE (editor) 1998.
80. Singh N, Gayowski T, Wagener MM, Marino IR. Causes of leukocytosis in liver transplant recipients: relevance in clinical practice. Transplantation 1998; 65:199-203.
81. Vergis EM, Paterson DL, Singh N. Indinavir associated hepatitis in patients with advanced HIV infection. Int J STD and AIDS 1998; 9:53.
82. Chang FY, Singh N, Gayowski T, Drenning S, Wagener MM, Marino IR. Staphylococcus aureus nasal colonization and infections in liver transplant recipients. Transplantation 1998; 65:1169-1172.
83. Vargas E, Laskus T, Radkowski M, Poutous A, Want L, Lee R, Dodson F, Gayowski T, Singh N, Marino IR, Fung JJ, Zhang-Keck ZY, Kim JP, Rakela J. Hepatitis G virus coinfection in hepatitis C virus-infected liver transplant recipients. Transplantation 1997;64:786-788.
84. Paterson DL, Singh N. Nelfinavir associated hyperglycemia in HIV infected patients. Ann Pharmacotherapy 1998; 32:609.
85. Bonham A, Dominguez EA, Fukui M, Paterson D, Pankey, GA, Fung JJ, Singh N. Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. Transplantation 1998;66:1596-1604.
86. Singh N, Paterson DL. Human herpesvirus-6 infection in transplant recipients. Current Opinion in Organ Transplantation 1998; 3:137-142.
87. Nguyen MH, Kauffman, CA, Goodman RP, Squier C, Arbeit RD, Singh N, Yu VL. S. aureus nasal carriage and infection in HIV infected patients. Ann Intern Med 1999; 130:221-225.
88. Singh N. Infectious diseases in the liver transplant recipients. Seminars in Gastrointestinal Disease 1998; 9:136-146.
89. Paterson DL, Singh N, Gayowski T, Marino IR. Mycobacterium mucogenicum: an unusual cause of bacteremia in cirrhosis. Am J Gastroenterol 1998;27:346-347.
90. Singh N. Infections in solid organ transplant recipients. Current Opinion in Infectious Diseases 1998; 11:411-417.
91. Singh N, Paterson DL. Mycobacterium tuberculosis infection in organ transplant recipients: impact and implications for management. Clinical Infect Dis 1998;27:1266-1277.
92. Singh N, Gayowski T, Marino IR. Quality of life, depression and functional status of liver transplant recipients with recurrent Hepatitis C virus hepatitis. Transplantation 1999;67:69-72.
93. Vargas HE, Laskus T, Want LF, Radkowski, Poutous A, Lee R, Demetris A, Gayowski T, Marino IR, Singh N, Dodson F, Casavilla A, Fung JJ, Rakela J. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transplantation and Surgery 1998; 22-27.
94. Singh N. Fungal infections in solid organ transplant recipients. Mycology Observer 1998; 7:6-7.
95. Singh N, Gayowski T, Marino IR. Pulmonary infiltrates in liver transplant recipients in the
intensive care unit. Transplantation 1999; 67:1138-1144.
96. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999; 78:123-138.
97. Paterson DL, Singh N, Gayowski T, Carrigan DR, Marino IR. Human herpesvirus-6 encephalitis in a liver transplant recipient. Liver Transplantation and Surgery 1997; 5:454-455.
98. Singh N, Gayowski T, Chang FY, Paterson DL, Marino IR. Predicting bacteremia and mortality in bacteremic liver transplant recipients. Liver Transplantation 2000;6:54-61.
99. Paterson D, Singh N, Gayowski T, Marino R. Fatal infection due to Escherichia
coli producing an extended spectrum beta-lactamase: implications for antibiotic choice in treatment of spontaneous bacterial peritonitis. Clin Infect Dis 1999; 28: 683-684.
100. Paterson D, Gayowski T, Wagener MM, Marino IR, Singh N. Quality of life in long-term survivors after liver transplantation: impact of recurrent viral HCV hepatitis. Clinical Transplantation 2000;14:48-54.
101. Paterson DL, Singh N, Panebianco A, Wannstedt CA, Wagener MM, Gayowski T, Marino IR. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation 1998; 66:593-598.
102. Swindells S, Mohr J, Justis J, Berman S, Squier CS, Wagener MM, Singh N. Quality of life in human immunodeficiency virus infected patients: impact of social support, hopelessness, and coping. Int J STD and AIDS 1999; 10(6):383-391.
Paper cited in Current Awareness in Biomedicine 1999; July.
103. Singh N, Berman S, Justis J, Swindells S, Mohr J, Squier C, Wagener, MM. Adherence with antiretroviral therapy in patients with human immunodeficiency virus infection: psychosocial determinants and role of coping responses. Clinical Infect Dis 1999;29:824-830.
104. Singh N, Yu VL. Mandatory research in intensive care units: implications for appropriate antibiotic prescription practices. Chest 2000; 117:1496-1499.
105. Singh N, Bonham, A., Fukui M. Immunosuppressive associated leukoencephalo-pathy in organ transplant recipients. Transplantation 2000;69:467-472.
106. Chang FY, Singh N, Gayowski T, Wagener M, Marino TR. Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, outcome and role of endogenous thrombopoietin. Transplantation 2000;69:70-75.
Paper cited in Current Awareness in Biomedicine, April 2000
107. Singh N, Chang FY, Gayowski T, Wagener MM, Marino IR. Fever in liver transplant recipients in the intensive care unit. Clinical Transplantation 1999:13;504-511.
108. Gayowski T, Wagener MM, Marino R, Singh N. Quality of life and functional status of liver transplant recipients with recurrent viral hepatitis C. Transplantation Proceedings 1999; 31:1386-1387.
109. Paterson DL, Staplefeldt W, Wagener MM, Gayowski T, Marino IR, Singh N. Intraoperative hypothermia is an independent risk factor for cytomegalovirus infection in liver transplant recipients. Transplantation 1999; 67:1151-1155.
110. Gayowski T, Singh N, Keyes L, Wannstedt C, Vargas H, Wagener MM, Laskus T, Rakela J, Marino IR. Late-onset renal failure in liver transplant recipients: role of posttransplant alochol use. Transplantation 2000;69:383-388.
111. Singh N, Rogers P, Atwood CA, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for suspected pulmonary infiltrate in the intensive care unit: a proposed solution for indiscriminate antibiotic use. Am J Resp Crit Care Med 2000;162:505-511.
Article cited in ACP Journal Club 2001; 134:45.
Also cited in Current Infectious Disease report 2001; 3:481-482
(Rating: of Importance).
Study reviewed in "Infectious Disease Alert" 2001; 20(1):4-5.
Article selected for publication in 2002 Mosby Year Book of Medicine.
Rated amongst top 1% of the citations in the field as per Essential Science Indicators 2005.
112. Singh N. Infectious diseases in liver transplant recipients. Liver Clinics of North America 2000; 4:657-673.
113. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Infections due to methicillin-resistant S. aureus in liver transplant recipients: the other emerging resistant gram-positive coccus in liver transplant recipients. Clinical Infectious Disease 2000;30:322-327.
114. Singh N. Mycobacterium tuberculosis: prevention and treatment in organ transplant recipients. Current Opinion in Organ Transplantation 1999;4:281-284.
115. Singh N, Yu VL. Opportunistic infections in acquired immune deficiency syndrome: moving targets and changing shadows. Infections in Medicine 2000;Feb:118-119.
116. Rogers J, Singh N, Carrigan DR, Rohal S, Kusne S, Knox KK, Wagener MM, Fung J. Human herpesvirus-6 infection in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and impact on outcome. Transplantation 2000; 69:2566-2573.
Article selected for publication in Mosby 2002 Year Book of
Pulmonary Disease
117. Singh N, Paterson D.L. Encephalitis due to human herpesvirus-6: clinical
relevance of a novel neurotropic virus in transplant recipients. Transplantation
2000; 69:2474-2479.
118. Singh N. Invasive Mycoses in organ transplant recipients: controversies in
prophylaxis and management. J Antimicrob Chemotherapy 2000;45:749-755.
119. Singh N, Hussain S. Infections of the central nervous system in transplant
recipients. Transplant Infect Dis 2000; 2:101-111.
120. Paterson DL, Swindells S, Mohr J, Brester M, Squier C, Wagener MM, Vergis EM,
Singh N. Adherence to protease-inhibitor therapy in patients with human immunodeficiency virus infection. Ann Intern Med 2000;133:21-30.
121. Singh N. Antifungal prophylaxis in solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000; 31:545-553.
122. Singh N. Infections in organ transplant recipients. Current Opinion Infect Dis
2000;13:343-347.
123. Singh N. Factors affecting the quality of life in patients with HIV infection. The
AIDS reader 2001; 11:450-461.
124. Singh N. Recent advances in the treatment of infections in liver transplant
recipients. Current Infectious Disease Reports 2001; 3:123-130.
125. Singh N, Gayowski T, Rihs JD, Wagener MM, Marino IR. Evolving trends in multiply antibiotic-resistant bacteria in liver transplant recipients: a 10 year study of antimicrobial susceptibility patterns. Liver Transplantation 2001;7:22-26.
126. Singh N. Herpesviruses 6, 7, and 8 in transplantation. Clin Microbiol and Infection 2000;6:453-459.
127. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with lipid preparation of amphotericin B for the prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Transplantation 2001; 71:910-913.
128. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus i.v. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 2000; 70:717-722.
129. Singh N. Universal versus preemptive prophylaxis for cytomegalovirus with ganciclovir in organ transplant recipients. Clin Infect Dis 2001; 32:742-751.
130. Singh N, Gayowski T, Wagener MM, Marino IR. Pretransplant dialysis associated morbidity and impact on fungal infections in liver transplant recipients. Liver Transplantation 2001;7:100-105.
131. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: correlates of variability in clinical characteristics and outcome. Emerging Infectious Diseases 2001;7:1-7.
132. Paterson D.L., Muder R.R., Squier C., Rihs B.L., Rihs J.D., Singh N. Outbreak of infection with E. coli harboring an extended-spectrum beta-lactamase in a liver transplant unit: could norfloxacin administration to carriers contribute to control? Clin Infect Dis 2001; 33:126-128.
133. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol and Infection 2001; 7:1-7.
134. Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. Int J STD and AIDS 2001; 12:463-468.
135. Singh N, Wagener MM, Gayowski T. Seasonal pattern of early mortality and infectious complications in liver transplant recipients. Liver Transplantation 2001; 7:884-889.
136. Husain S, Singh N: Pyomyositis due to bacillary angiomatosis in a HIV infected patient. Infection 2002; 30:50-53.
Article abstracted in CSA Virology and AIDS abstracts database
137. Singh N. Antimicrobial strategies for the prevention of infections in liver transplant recipients. Infections in Medicine 2002; 19:428-435.
138. Husain S, Dauber J, McCurry K, Singh N, Kusne S. Nocardia infections in lung transplant recipients. J Heart Lung Transplantation 2002; 21:354-359.
139. Hauser D, Gayowski T, Singh N. Bleeding complications precipitated by unrecognized gingko biloba use in a liver transplant recipient. Transplant International 2002; 15:377-379.
140. Singh N. Fungal infections in liver and kidney transplant recipients. Current Treatment Options in Infectious Diseases 2001; 3:507-513.
141. Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002; 73:63-67.
142. Singh N, Husain S, Carrigan DR, Weck KE, Wagener MM, Gayowski T. Impact of viremia due to human herpesvirus-6 on the frequency and severity of recurrent HCV hepatitis in liver transplant recipients. Clin Transplantation 2002; 16:92-96.
143. Singh N. Trends in the epidemiology of opportunistic invasive fungal infections:
Prediposing factors and antimicrobial agent usage practices. Clin Infect Dis 2001; 33:1692-1696.
144. Singh N, Bentlejewski C, Carrigan DR, Gayowski T, Zeevi A. Persistent lack of human herpesvirus-6 specific T-helper cell response in liver transplant recipients. Transplant Infect Dis 2002; 4:59-63.
145. Singh N. Fungal infections in liver transplant recipients. Infectious Disease Clinics of North America 2003; 17:113-134.
146. Squier C, Rihs J, Risa K, Saginemeni A, Stout J, Wagener MM, Muder RR, Singh N. S. aureus nasal carriage and association with infections in intensive care unit and liver transplant unit patients. Infect Control Hosp Epidemiol 2002; 23:495-501.
147. Singh N. Cytomegalovirus infection in liver transplant recipients: comparison of antigenemia and molecular biology assay. Liver Transplantation 2001; 7:1004-1007.
148. Husain S, Singh N. Impact of novel immunosuppressive agents on infectious complications in transplant recipients. Clin Infect Dis 2002; 35:53-61.
149. Singh N, Husain S. Aspergillus infections in lung transplant recipients: differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22:258-266.
150. Singh N. Imaging findings in invasive zygomycosis. Liver Transplantation 2002; 8:306-307.
151. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the
metabolism of tacrolimus in liver transplanat recipient and in human liver microsomes. Antimicrob Ag Chemother 2002; 46:3091-3093.
152. Paterson DL, Rihs JD, Squier CS, Gayowski, T., Singh, N. Lack of efficacy of
mupirocin in the prevention of infections with methicillin-resistant Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 2003; 75:194-198.
153. Singh N, DL Paterson. Cryptococcus neoformans infection (Imaging findings in
liver transplantation). Liver Transplantation 2002; 74:892-895.
154. Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid
chemoprophylaxis employed during liver transplant candidacy for the prevention of posttransplant M. tuberculosis infection. Transplantation 2002; 74:892-895.
Paper cited in Drug Week (2-20-02), source CDC
HIV/STD/TB Prevention News Update
155. Husain S, Singh N. Burkholderia cepacia complex in lung transplant recipients.
Seminars Resp Infect 2002; 17:310-414.
156. Husain S, Singh N. Role of infections in obliterative bronchitis in lung transplant recipients. Seminar Resp Infect 2002; 17:284-290.
157. Husain S, Tollemar J, Dominguez EA, Baumgarten K, Humar A, Paterson DL, Wagener MM, Kusne S, Singh N. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003 75:2023-2029.
158. Singh N. Delayed occurrence of cytomegalovirus disease in transplant recipients:
have we won the battle only to lose the war? Eur J Clinical Microbiol and Infect Dis 2002; 21:643-646.
159. Singh N, Yu VL. Legionnaires' disease in transplant recipients: nosocomial or
home-grown? Transplantation 2002; 74:755-756.
160. Singh N. Impact of donor bacteremia in organ transplant recipients. Liver Transplantation 2002; 8:975-976.
161. Singh N, Wagener MM, Gayowski T. Changing epidemiology and predictors of mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit.
Clinical Microbiol Infection 2003; 9(6):531-538.
162. Singh N. Avery RK, Munoz P, Pruett TL, Alexander B, Jacobs R, Dominguez EA, Yu CM, Paterson DL, Kusne S, Linden P. Trends in risk-profiles and mortality due to invasive aspergillosis in liver transplant recipients. Clinical Infect Dis 2003; 36:46-52.
163. Singh N. Changing face of invasive aspergillosis in liver transplant recipients. Liver
Transplantation 2002; 8:1071-1072.
164. Singh N. Impact of current transplantation practices on the changing epidemiology
of infections in transplant recipients. The Lancet Infectious Diseases 2003;
3:156-61.
165. Marino IR, Panarello G, Singh N. Efficacy of Aspergillus galactomannan directed
preemptive therapy for the prevention of invasive aspergillosis in organ transplant
recipients. Transplant Infect Dis 2002; 4:1-2.
166. Risa KJ, Nepon L, Justis JC, Panwalker A, Berman SM, Cinti S, Wagener MM,
Singh N. Alternative therapy use in HIV-infected patients receiving highly active
antiretroviral therapy. Int J STD & AIDS 2002; 13:706-713.
167. Singh N. Optimal antiviral therapy for prophylaxis of cytomegalovirus: ganciclovir versus foscarnet. Evidence-based Oncology 2002; 3:128-130.
168. Paterson DL, Singh N. Infective endocarditis in solid organ transplant recipients. Infection 2003; 271-282.
169. Husain S, Alexander B, Munoz, P, Avery RK, Houston S, Pruett T, Jacobs R, Dominguez EA, Tollemar JG, Yu CM, Wagener MM, Linden P, Kusne S, Singh N. Opportunistic mycelial fungi in organ transplant recipients: Emerging importance of non-Aspergillus mycelial infections. Clin Infect Dis 2003; 37:221-22
170. Singh N. Antifungal prophylaxis in solid organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004; 39:S200-206.
171. Singh N. Treating opportunistic mycoses: how long is long enough? The Lancet Inf Dis
2003; 3:703-708.
172. Singh N, Wannstedt C, Keyes L, Devera M, Cacciarelli TV, Wagener MM, Gayowski T. Impact of evolving trends in recipients and donor characteristics on cytomegalovirus infection in liver transplant recipients. Transplantation 2004; 77:106-110.
173. Husain S, Kwak EJ, McLaughlin L, Obman A, Stout JE, Mitchell L, Ferrera C, Kusne S, Bentsen C, McCurry K, Singh N. Prospective assessment of Platelia Aspergillus galactomannan for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4:796-802.
174. Singh N, Bentlejewski C, Wagener MM, Gayowski T, Zeevi A. T-helper cell responses in liver transplant recipients: correlation with cytomegalovirus and other major infections. Transplant Infectious Diseases 2004; 6:93-96.
175. Singh N, Paterson DL. Aspergillus infection in transplant recipients. Clin Microbiol Reviews 2005; 18:44-69.
176. Singh N, Husain, DeVera M, Cacciarelli TV, Gayowski T. Cryptococcus neoformans infections in patients with cirrhosis and liver transplant candidates. Medicine 2004;83:188-192.
177. Kwak EJ, Husain S, Obman A, Ferrera C, Meinke L, Stout J, Kusne S, Wagener MM, Singh N. Efficacy of galactomannan antigen using Platelia Aspergillus enzyme immunoassay for the diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004; 42:435-453.
178. Singh N, Wagener MM, Obman A, Cacciarelli TV, De Vera ME, Gayowski T.
Temporal trends in bacteremias in liver transplant recipients: shift towards gram-negative bacteria as predominant pathogens. Liver Transplantation 2004;10:844-849.
179. Singh N, Obman A, Husain S, Aspinall S, Mietzner S, Stout JE. Reactivity of Platelia Aspergillus glactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable serum concentrations. Antimicrob Agents Chemother 2004; 48:1989-1992.
180. Singh N, Heitman J. Antifungal attributes of immunosuppressive agents – new
paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation 2004;
77:795-800.
181. Yu VL, Singh N. Excessive antibiotic usage causes measurable harm in patients
with suspected ventilator associated pneumonia. Intensive Care Medicine 2004;
30:735-738.
182. Husain S, Munoz P, Forrest G, Alexander B, Somani J, Brennan K, Wagener MM, Singh N,. Infections due to Scedosporium apiospermum and prolificans: Clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40:89-99.
183. Steinbach WJ, Singh N, Miller JL, Benjamin DK, Schell WA, Heitman J, Perfect JR. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and non-transplant patients. Antimicrob Agents Chemother 2004; 48:4922-4925.
184. Blankenship JR, Singh N, Alexander BD, Heitman J. Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by immunosuppressive regimens. J Antimicrob Chemother 2005; 43:464-467.
185. Singh N. Interactions between viruses in transplant recipients. Clin infect Dis 2005; 40:430-436.
186. Singh N, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir as preemptive therapy for CMV disease in liver transplant recipients: Impact on viral load and late-onset CMV disease. Transplantation 2005; 79:85-90.
187. Singh N. Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis and management. Medical Mycology 2005; 43:267-270.
188. Singh N. Late-onset cytomegalovirus disease as a significant complication in organ transplant recipients receiving antiviral prophylaxis: a call to heed mounting evidence. Clin Infect Dis 2005; 40:704-708.
189. Singh N, Stout JE, Yu VL. Prevention of Legionnaires’ disease in transplant recipients; recommendations for a standardized approach. Transplant Infect Dis 2004; 6:58-62.
190. Singh N, Husain S. Recommendations for screening, monitoring, and reporting of fungal infections in clinical trials in recipients of organ transplantation. Am J Transplant 2006; 5:262-274.
191. Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005; 79:1428-1434.
192. Singh N, Yu VL. Severing the Gordian Knot of prevention of cytomegalovirus in liver transplant recipients: the principle is the sword. Liver Transplantation 2005; 8:891-894.
193. Singh N, Wannstedt C, Keyes, L, Wagener MM, Cacciarelli TV. Impact of an aggressive infection control strategy on endemic S. aureus infections in liver transplant recipients. Infect Control Hosp Epidemiol 2006; 27:122-126.
194. Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Who amongst CMV seropositive liver transplant recipients are at risk for CMV infection? Liver Transplantation 2005; 11;700-704.
195. Borerro S, Singh N. Epidural abscess of an unusual etiology in a previously healthy man. Infections in Medicine 2006; 23:35-36.
196. Singh N, Lortholary O, Alexander BD, Gupta KL, John GT. Pursell KJ, Muñoz P, Klintmalm GB, Stosor V, del Busto R, Limaye AP, Somani J, Lyon M, Houston S, House AA, Pruett TL, Orloff S, Humar A, Dowdy LA, Garcia-Diaz J, Kalil AC, Fisher RA, Heitman J, Husain S, and the Cryptococcal Collaborative Transplant Study Group. Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcal neoformans infection. Transplantation 2005; 80:1033-1039.
197. Singh N. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor based immunosuppression. Current Opinion Infect Dis 2005; 18:342-345.
198. Singh N, Limaye A, Safdar N, Muñoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, del Busto R, Aguado JM, Wagener MM, Husain S. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: prospective, multicenter, observational trial. Transplantation 2006; 81:320-326.
Published as a “Rapid Communication” article.
199. Singh N. Cytomegalovirus in solid organ transplant recipients: new challenges and their implications for prophylactic strategies. J Clin Virol 2006; 35:474-477.
200. Squier C, Krystofiak S, Singh N. Infections in solid organ transplant recipients.
APIC Text, Infection Control and Epidemiology 2005; 436:1-9.
201. Singh N, Lortholary O, Alexander BD, Gupta KL, John G, and the Cryptococcal1 Collaborative Transplant Study Group. Allograft loss in renal transplant recipients with C. neoformans associated immune reconstitution syndrome. Transplantation 2005; 80:1131-1133.
202. Singh N, Husain S, Limaye AP, Pursell K, Klintmalm GB. Pruett TL, Somani J, Stosor V, del Busto R, Steele C. Systemic and cerebrospinal fluid cytokine responses in organ transplant recipients with Cryptococcus neoformans infection. Transplant Immunology 2006; 16:69-72.
203. Tickerhoof L, Wagener MM, Cacciarelli TV, Singh N. Alternative therapy use in liver transplant recipients. Progress in Transplantation 2006; 16:226-231.
204. Reedy JL, Husain S, Ison M, Pruett TL, Singh N, Heitman J. Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin-inhibitors in invasive Candida albicans isolates from liver transplant recipients. Antimicrob Agents Chemother 2006; 50:1573-1577.
205. Singh N, Limaye AP, Forrest G., Safdar N, Muñoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, del Busto R, Aguado JM, Wagener MM, Husain S. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Medical Mycology 2006; 44:445-449.
206. Singh N, Pruett TL, Houston S, Munoz P, Cacciarelli T, Wagener MM, Husain S. Invasive aspergillosis in the recipients of liver retransplantation. Liver Transplantation 2006; 12:1205-1209.
207. Singh N. Optimization of outcomes related to cytomegalovirus in organ transplant recipients. Transplantation 2006; 82:15-16.
208. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Medical Virology 2006; 16:281-287.
202. Singh N, Husain S, Limaye AP, Pursell K, Klintmalm GB. Pruett TL, Somani J, Stosor V, del Busto R, Steele C. Systemic and cerebrospinal fluid cytokine responses in organ transplant recipients with Cryptococcus neoformans infection. Transplant Immunology 2006; 16:69-72.
209. Singh N, Lortholary O, Alexander BD, Gupta KL, John GT, Pursell K, Munoz P, Klintmalm GB, Stosor V, del Busto R, Limaye AP, Somani J, Lyon M, Houston S, House AA, Pruett TL, Orloff S, Humar A, Dowdy L, Garcia-Diaz J, Kalil AC, Fisher RA, Husain S, and the Cryptococcal Collaborative Study Group. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients Clin Infect Dis 2005; 40:1756-61.
210. Jalali Z, Ng L, Singh N, Pirofski L. Antibody response to Cryptococcus neoformans capsular polysaccharide glucronoxylomannan in patients with solid organ transplants. Clinical Vaccine Immunology 2006; 13:740-746.
211, Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. The Lancet Infect Dis 2007;7: 395-401.
212. Munoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with
invasive fungal infections: should the combination of antifungal drugs be used? Current Opinion Infect Dis 2006; 19:365-370.
213. Husain S, Chan K, Palmer SM, Hadjiliadis D, Humar A, Wagener MM, McCurry
KR, Singh N. Bacteremia in lung transplant recipients in the current era. Am J Transplant 2006; 6:3000-3007.
214. Husain S, Paterson DL, Studer S, Crespo M, Pilewski J, Durkin M, Wheat LJ. Johnson B, McLaughlin L, Bentsen C, McCurry KR, Singh N. Prospective assessment of Platelia Aspergillus EIA in the bronchoalveolar lavage fluid for early diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007;83:1330-1336.
215. Singh N. Antimicrobial strategies for the prevention of infections in liver transplant recipient. Infections in Medicine 2006; 23:547-562.
216. Singh N, Alexander BD, Lortholary O, Gupta KL, John GT, del Busto R, Klintmalm GB, Somani J, Lyon M, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Wagener MM, Husain S, and the Cryptococcal Collaborative Transplant Study Group. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007;195:756-764.
Article selected for publication in Surgery News, International
Medical News Group of Elsevier Publications.
217. Waterman S, Hacham M, Hu G, Zhu X, Shin S, Panepinto J, Valyi-Nagy T,
Husain S, Singh N, Williamson PR. Role of the Cuf1-CTR4 copper regulatory
axis in the virulence of Cryptococcus neoformans. J Clin Invest 2007;117:794-
218. Lungman P, Singh N. Human herpesvirus-6 in stem cell and solid organ transplant recipients. J Clin Virol 2007;37: 87-91.
219. Singh N. Hypercalcemia related to immune reconstitution syndrome in organ transplant recipients with granulomatous opportunistic infections. Transplantation 2006; 82:986.
220. Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV, Frye R. Hepatic iron content and outcome of S. aureus bacteremia in liver transplant recipients. Progress in Transplant 2007 (in press).
221. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, et al. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis 2006; 43:1031-1039.
222. Saha DC,Goldman DL, Shao X, Casadevall A, Husain S, Limaye AP, Lyon M, Somani J,
Pursell K, Pruett TL, Singh N. Serologic evidence for reactivation cryptococcosis in
solid organ transplant recipients. Clinical Vaccine immunology (under review).
223. Singh N, Perfect JR. Immune reconstitution and paradoxical exacerbation of infections following pregnancy. Clin Infect Dis (under review).
224. Bonatti H, Sawyer R, Dickson RC, Razonable R, Machicao V, Mendez J,
Singh N, Pruett T. Transmission of viral disease to the recipient through donor liver. Curr Opinion Transplant 2007 (in press).
225. Bonatti H, Lass-Flörl C, Zelger B, Singh N, Lottersberger, C, Margreiter R, Schnesberger, S. Alternaria alternata soft tissue infection in a forearm transplant recipient. Surgical Infect 2007 ( in press).
226. Bonatti H, Angerer K, Singh R, Singh N, Stelzmueller I, Lechner M, Margreiter T, Schmid T, Loss-Floerl C. Successful management of post-pneumonectomy pleural aspergillosis by combined surgical and antifungal approach with voriconazole and caspofungin (under review).
227. Singh N, Wannstedt C, Keyes L, Mayher D, Wagener MM, Akoad M, Cacciarelli TV. Valganciclovir as preemptive therapy for cytomegalovirus in CMV-seronegative liver transplant recipients of CMV-seropositive donor allografts. Liver Transplant (under review).
228. Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients (under review).
229. Singh N, KJ Pursell. Combination therapy for invasive aspergillosis in transplant recipients. Mycoses (under review).
230. Singh N, Alexander BD, Lortholary O, Gupta KL, John GT, del Busto R, Klintmalm GB, Somani J, Lyon M, Pursell K, Stosor V, Munoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Wagener MM, Husain S, and the Cryptococcal Collaborative Transplant Study Group. Pulmonary cryptococcosis in organ transplant recipients: clinical relevance of cryptococcal antigen (under review).
231. Singh N. Inching closer towards optimization of prophylaxis for latent tuberculosis in organ transplant recipients. Transplantation 2007:83;1536-1537.
232. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation in North America. Am J Transplant 2007
BOOK CHAPTERS
1. Singh N. Infections in solid-organ transplant recipients. In RP Wenzel (ed). Prevention and Control of Nosocomial Infections. Lippincott Williams and Wilkins, Baltimore, MD, 1997, Third edition, 1100-1135.
2. Tami TA, Gold S, Singh N. AIDS in otolaryngology. Yu VL and Johnson J (eds). Infectious Diseases and Antimicrobial Therapy of the Ear Nose and Throat. W.B. Saunders, 1996.
3. Singh N, Carrigan DR. Human herpesvirus-6 infections. In Yu VL, Merigan T (eds). Antimicrobial Agents and Vaccines. Lippincott Williams and Wilkins, Baltimore, MD, 1998; 1260-1263.
4. Paterson DL, Singh N. Pulmonary infections in immunocompromised hosts. Critical Care Medicine, 4th Edition, Shoemaker, Ayres, Gervenick, Holbrook (eds), WB Saunders. Philadelphia, 1999; 698-715.
5. Paterson DL, Singh N. Fungal infections of the lung in organ transplant recipients. In:
Fungal infections of the Lung. Sarosi GA and Davies SF (eds.), 1998. Lippincott Williams and Wilkins, New York 1999; 239-269.
6. Clancy N, Singh N. Infections due to dematiaceous fungi. In: Yu VL, Merigan T (eds).
Antimicrobial Agents and Chemotherapy, Lippincott Williams and Wilkins, 1998.
7. Singh N. Nosocomial infections in solid organ transplant recipients. In: Infection Control
and Hospital Epidemiology. C. Glenn Mayhall (editor), Lippincott, Williams and Wilkins,
Baltimore, 1999;781-802.
8. Singh N. Infections in critically ill solid organ transplant recipients. In: Critical Care
Infectious Diseases. Rello J, Valles J, Kollef M (editors), Kluwer Academic Publishers
2001; 77-107.
9. Paterson DL, Singh N. Respiratory infections in immunocompromised non-neutropenic
patients. In: Critical Care Infectious Diseases. Rello J, Valles J, Kollef M (editors), Kluwer Academic Publishers. 2001; 677-717.
10. Singh N. Posttransplant fever in critically ill organ transplant recipients. Singh N., Aguado, J.M. (editors). Infectious Complications in Transplant Recipients, Kluwer Academic Publishers 2001;113-132.
11. Butt A, Singh N. Hepatitis C virus: Prevention, Therapy and Role of Transplantation. In: "Prevention and Control of Nosocomial Infections." Richard P. Wenzel (editor). Lippincott, Williams and Wilkins, Fourth Edition, 2003.
12. Singh N. Human herpesvirus 6, 7, and 8 in stem cell and organ transplant recipients. Bowden RA, Ljungman P, Paya CV (editors). In: Transplant Infections, Lippincott Williams and Wilkins, 2003.
13. Ljungman P, Singh N. Human herpesvirus-6 and transplantation. In Human herpesvirus-6: general virology, epidemiology and clinical pathology. Kreuger GRF and Ablashi DV (editors). Elsevier Science Publishers, Amsterdam 2006; 279-290.
14. Singh N. Respiratory tract infections in solid organ transplant recipients. In: Respiratory Infections. Torres A, Ewig S, Mandell L, Woodhead M (editors). Arnold Health Sciences, London, UK (in press).
ABSTRACTS
1. Singh N, Dummer JS, Kusne S, Ho M. Cytomegalovirus infection in adult liver transplant recipients. (Abstract), American College of Physicians, Western Pennsylvania, Chapter, Pittsburgh, PA, 1987.
2. Singh N, Dummer JS, Makowka L, Starzl TE, Ho M. Impact of OKT3 antibodies on cytomegalovirus and herpes simplex virus infections in adult liver transplant recipients. (Abstract #PL62), International Organ Transplant Forum, Pittsburgh, 1987.
3. Kusne S, Dummer JS, Singh N, Ho M. Infections after adult liver transplantation. (Abstract) American College of Physicians, Western Pennsylvania Chapter, Pittsburgh, PA, 1987.
4. Kusne S, Dummer JS, Singh N, Makowka L, Starzl TE, Ho M. Fungal infections in adult liver transplant recipients. (Abstract #PL63). International Organ Transplant Forum, Pittsburgh, PA, 1987.
5. Singh N, Rihs D, Mieles L, Gayowski T, Yu VL. Improved detection of spontaneous bacterial peritonitis with Bactec as compared to conventional culture methods: a prospective study. (Abstract) Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, CA, 1992.
6. Singh N, Mieles L, Gayowski T, Miner RC, Yu VL. Failure of high dose acyclovir and success of pulse ganciclovir therapy in preventing cytomegalovirus disease in liver transplant recipients: a prospective, randomized trial (Abstract). Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, CA, 1992.
7. Gayowski T, Singh N, Mieles L, Wagener M, Yu VL. Failure of acyclovir and successful prophylaxis for cytomegalovirus disease in liver transplant recipients with short course preemptive ganciclovir therapy: A prospective randomized trial (abstract). Second Congress of the International Liver Transplantation Society, Toronto, Canada, 1993.
8. Singh N, Gayowski T, Wagener MM, Yu VL. Recurrent hepatitis C virus (HCV) hepatitis after liver transplantation: association with increased immunosuppression post transplant. (Abstract) Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993.
9. Singh N, Gayowski T, Yu VL. Central nervous system (CNS) lesions in liver transplant recipients: presumptive diagnosis based on timing and clinical presentation.
(Abstract) Interscience conference on Antimicrobial Agents and Chemotherapy. New
Orleans, LA, 1993.
10. Singh N, Mieles L, Yu VL, Gayowski T. Invasive aspergillosis in liver transplant recipients: association with candidemia and consumption coagulopathy and failure of prophylaxis with low dose intravenous amphotericin B. (Abstract). Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993.
11. Singh N, Gayowski T, Wagener M, Yu VL. Infectious complications in a liver transplant recipients on FK506 (tacrolimus): Prospective analysis of 88 consecutive liver transplants. (Abstract). Interscience conference on antimicrobial agents and chemotherapy. Orlando, FL, 1994.
12. Singh N, Squier C, Hayes P, Wagener M, Sivek C, Goetz A, Nguyen MH, Yu VL. Determinants of compliance in patients with HIV: prospective assessment with implications for enhancing compliance. (Abstract). Interscience conference on antimicrobial agents and chemotherapy. Orlando, FL, 1994.
13. Singh N, Gayowski T. Lack of sustained efficacy of combination ganciclovir and foscarnet therapy for hepatitis B virus recurrence after liver transplantation. (Abstract). Infectious Disease Society of America. Orlando, FL, 1994.
14. Singh N, Gayowski T, Wagener MM, Yu VL. Trimethoprim sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: A prospective randomized trial. (Abstract) American Association for the Study of Liver Diseases, 45th Annual Meeting, Chicago, IL, 1994.
15. Singh N, Gayowski T, Wagener MM, Yu VL. Trimethoprim sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a prospective randomized trial. (Abstract #75) Hepatology 1994; 20:115A.
16. Singh N, Rihs JD, Gayowski T, Yu VL. Correlation of ascitic fluid inflammatory cell response with causative bacteria in spontaneous bacterial peritonitis: a prospective study (Abstract #1214). Hepatology, 1994; 20:401A.
17. Singh N, Gayowski T, Hauser D, Wagener MM, Yu VL. Factors influencing survival in patients with endstage liver disease requiring intensive care unit management. A prospective study (Abstract #1217). Hepatology 1994; 20:401A.
18. Singh N, Gayowski T, Carrigan DR. Variant B human herpesvirus 6 associated acute febrile illness with thrombocytopenia, encephalopathy, and dermatosis in a liver transplant recipient (Abstract #1216). Hepatology 1994; 20:401A.
19. Singh N, Gayowski T, Wagener MM, Hauser D, Yu VL. Predictors of mortality during intensive care unit stay in liver transplant recipients: A prospective study. (Abstract #1215). Hepatology 1994;20:401A.
20. Singh N, Gayowski T, Wagener MM, Yu VL. Successful prophylaxis of spontaneous bacterial peritonitis with trimethoprim sulfamethoxazole in cirrhotic ascites. (Abstract) Interscience conference on antimicrobial agents and chemotherapy, Orlando, FL, 1994.
Abstract accepted for the late-breaker session.
21. Singh N, Gayowski T, Hauser D, Wagener M, Yu VL. Outcome of patients with cirrhosis requiring intensive care unit management: prospective assessment of predictors of mortality. (Abstract #P 0232) Society of Critical Care Medicine, 24th Educational and Scientific Symposium, San Francisco, CA, 1995.
22. Singh N, Gayowski T. Acute adrenal insufficiency in critically ill liver transplant recipients (Abstract #T 0233). Society of Critical Care Medicine, 24th Educational and Scientific Symposium, San Francisco, CA, 1995.
23. Singh N, Gayowski T, Hauser D, Wagener M, Yu VL. Mortality during intensive care unit stay in liver transplant recipients: prospective assessment of predictors of outcome. (Abstract #T 0234). Society of Critical Care Medicine, 24th Educational and Scientific Symposium, San Francisco, CA, 1995.
24. Goetz A, Muder RR, Rihs JP, Chow JW, Singh N. An outbreak of infusion-related Klebsiella pneumoniae bacteria on a liver transplantation service. (Abstract) 22nd annual education conference and international meeting of association of practitioners in infection control. Las Vegas, Nevada, 1995.
25. Nugyen MN, Kauffman C, Arbeit R, Goodman D, Squier C, Singh N, Wagener MM, Yu VL. Staphylococcus aureus nasal carriage and infection in HIV-infected patients (Abstract) 35th Interscience conference on antimicrobial agents and chemotherapy. San Francisco, CA, 1995.
26. Singh N, Gayowski T, Wagener MM, Yu VL. Infectious complications in liver transplant recipients with recurrent hepatitis C virus hepatitis. (Abstract) 35th Interscience conference on antimicrobial agents and chemotherapy. San Francisco, CA, 1995.
27. Singh N, Squier C, Sivek C, Nguyen MH, Wagener MM, Yu VL. Determinants of nontraditional therapy use in patients with HIV infection. (Abstract) Interscience conference on antimicrobial agents and chemotherapy. San Francisco, CA, 1995.
28. Singh N, Gayowski T, Wagener MM, Wannstedt CF, Marino IR. Interferon-alpha therapy for hepatitis C virus hepatitis after liver transplantation. (Abstract) 35th Interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, 1995.
29. Gayowski TJP, Marino IR, Doyle HR, Singh N, Todo S, Wagener MM, Mieles L, Fung JJ, Starzl TE. Primary liver transplantation in US veterans under FK506 immunosuppression (Abstract) VA Surgeon's Society meeting, Pittsburgh, PA, April 1995.
30. Singh N, Gayowski T, Wagener MM, Marino R. Increased infection in liver transplant recipients with recurrent hepatitis C virus (HCV) hepatitis (Abstract). American Association for the Study of Liver Diseases, 46th Annual Meeting, Chicago, IL, 1995.
31. Gayowski T, Singh N, Wannstedt CF, Marino IR, Wagener MM. Interferon-alpha therapy for hepatitis C virus (HCV) recurrence after liver transplantation: long term response with maintenance therapy (Abstract). American Association for the Study of Liver Diseases, 46th Annual Meeting, Chicago, IL, 1995.
This abstract was selected for discussion at the
meeting's poster review session.
32. Gayowski TJP, Marino IR, Doyle HR, Singh N, Todo S, Wagener MM, Mieles L. Fung JJ, Starzl TE. Primary liver transplantation in U.S. veterans under FK506 immunosuppression: a prospective trial (Abstract). American Association for the Study of Liver Diseases, 46th Annual Meeting, Chicago, IL, 1995.
33. Singh N, Rihs JD, Gayowski T, Yu VL. Correlation of ascitic fluid polymorphonuclear cell response with causative bacteria in spontaneous bacterial peritonitis (Abstract). Infectious Diseases Society of America, 33rd annual meeting, San Francisco, CA, 1995.
34. Singh N, Gayowski T, Wagener MM, Yu VL. Pulmonary infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression (Abstract). Infectious Diseases Society of America, 33rd annual meeting, San Francisco, CA, 1995.
35. Singh N, Squier C, Sivek C, Wagener MM, Yu VL. Psychosocial stress and depression in older patients with HIV: Implications for intervention (Abstract). Infectious Diseases Society of America, 33rd annual meeting, San Francisco, CA, 1995.
36. Singh N, Gayowski T, Marino IR. Pre-transplant famciclovir for prophylaxis of recurrent hepatitis B virus hepatitis after liver transplantation (Abstract). Infectious Diseases Society of America, 33rd annual meeting, San Francisco, CA, 1995.
37. Chang FY, Singh N, Gayowski T, Marino IR. Parvovirus B19 induced transfusion dependent anemia in an adult liver transplant recipient: effective treatment with intravenous immunoglobulin (Abstract). Infectious Diseases Society of America, 33rd annual meeting, San Francisco, CA, 1995.
38. Singh N, Gayowski T, Wagener MM, Doyle H, Marino IR. Risk factors for invasive fungal infections in liver transplant recipients receiving tacrolimus as primary immunosuppression (Abstract). Focus on Fungal Infections 6, New Orleans, LA, 1996.
39. Carrigan DR, Milburn G, Dienglewicz R, Kernan N, Papadopoulos E, Singh N. Diagnosis of active human herpesvirus six (HHV-6) infections in immuno-compromised patients with a rapid shell-vial assay. (Abstract). 96th Annual Meeting of the American Society of Microbiology, New Orleans, LA, 1996.
40. Bonham A, Singh N, Fukui M, Dominguez EA, Pankey GA, Paterson D, Fung JJ. Central nervous system (CNS) lesions in liver transplant r
|